Avita Medical AI Stock Analysis
Want to see RCEL full AI Analyst Report?
Avita Medical (RCEL) AI Stock Analysis
Avita Medical
(NASDAQ:RCEL)
RCEL’s score is driven by strong technical momentum and a very favorable earnings-call outlook (raised revenue guidance, high expected gross margins, and a stated path to near-term cash-flow breakeven with improved liquidity). These positives are tempered by weaker financial fundamentals—negative equity, ongoing net losses, and continued negative operating/free cash flow—plus limited valuation support due to the negative P/E and no dividend.
Avita Medical Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales across countries and regions to reveal where Avita is gaining traction and where growth depends on local approvals, reimbursement, or market access. Geographic concentration can expose the company to regulatory shifts, currency swings, or supply-chain disruption, while diverse regional sales point to broader commercial resilience.
Revenue is almost entirely U.S.-driven, with international markets contributing only noise—recent EU/UK/Japan blips haven’t meaningfully diversified the base. Management’s guidance and reimbursement wins hinge on normalization of ReCell utilization across ~200 core U.S. centers, so upside is execution- and payer-dependent; one remaining MAC and quarterly margin pressure from mix/reserves are key downside risks. The refinancing eases covenant risk, but durable growth requires sustained U.S. utilization recovery and successful commercialization of CoHiliX/PermeDerm.
Avita Medical (RCEL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $378.11M
- Dividend Yield
- ―
- Average Volume (3M)
- 432.07K
- Price to Earnings (P/E)
- -12.9
- Beta (1Y)
- 1.71
- Revenue Growth
- 16.96%
- EPS Growth
- 34.83%
- Country
- US
- Employees
- 226
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Avita Medical Business Overview & Revenue Model
Company Description
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harves...
How the Company Makes Money
Avita Medical primarily makes money by selling its RECELL System and associated single-use consumables used in each procedure (e.g., kits/components required to prepare the autologous skin cell suspension). Revenue is generated when hospitals, burn c...
Avita Medical Earnings Call Summary
The call was strongly positive. Revenue growth accelerated, RECELL adoption expanded, Cohealyx grew, PermeaDerm produced favorable clinical and economic results, gross margin improved, cash use declined substantially, liquidity strengthened through the additional $10 million credit-facility draw, and full-year guidance was raised for the second consecutive quarter. The main challenges were flat international RECELL and PermeaDerm revenue, continued net losses, lower margins for newer products, ongoing hospital adoption reviews, and some uncertainty around seasonal Q3 volume; these issues were outweighed by the reported operating and financial improvements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
AVITA raised full-year 2026 revenue guidance to $92 million-$94 million from $86 million-$89 million, representing approximately 28%-31% growth over 2025, with $93 million at the midpoint, compared with approximately $35 million in 2022 and a compound annual growth rate of approximately 28% over four years; the guidance implies Q4 revenue of approximately $24.9 million-$26.9 million and approximately 30% growth for the full year over 2025, while the company remains on track to achieve cash flow breakeven in the fourth quarter. RECELL gross margin is currently expected to remain between 85% and 90% over the coming quarters. For 2027, management is not providing formal guidance but said it expects to grow at a rate that it has been growing, keep operating expenses flat, and does not see headcount going up significantly, with commissions having some variability as revenue goes up.
Avita Medical Financial Statement Overview
Summary
Operating trajectory is improving (TTM revenue ~$84.7M with ~12% growth, very strong ~82% gross margin, EBITDA slightly positive), but the financial foundation is still weak: net margin remains deeply negative (~-43%), stockholders’ equity is negative (~-$31M), and cash generation is still negative (TTM operating cash flow ~-$19.7M; free cash flow ~-$18.1M). Overall, improving operations are offset by balance-sheet and cash-burn risk.
Income Statement
47NeutralBalance Sheet
24NegativeCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.68M | 71.61M | 64.25M | 50.14M | 34.42M | 33.02M |
| Gross Profit | 69.75M | 58.82M | 55.16M | 42.36M | 28.38M | 26.92M |
| EBITDA | -28.52M | -41.23M | -55.30M | -33.54M | -26.05M | -24.07M |
| Net Income | -36.12M | -48.59M | -61.84M | -35.38M | -26.66M | -25.14M |
Balance Sheet | ||||||
| Total Assets | 46.79M | 56.39M | 79.71M | 111.64M | 98.26M | 116.02M |
| Cash, Cash Equivalents and Short-Term Investments | 10.50M | 18.18M | 35.88M | 89.06M | 79.34M | 85.16M |
| Total Debt | 47.13M | 46.05M | 45.98M | 42.41M | 918.00K | 1.64M |
| Total Liabilities | 77.83M | 73.04M | 75.21M | 62.58M | 13.52M | 11.39M |
| Stockholders Equity | -31.04M | -16.65M | 4.50M | 49.06M | 84.74M | 104.62M |
Cash Flow | ||||||
| Free Cash Flow | -18.24M | -32.93M | -58.27M | -39.46M | -19.61M | -18.52M |
| Operating Cash Flow | -19.72M | -31.20M | -48.94M | -38.01M | -19.09M | -18.04M |
| Investing Cash Flow | 7.83M | 12.45M | 37.36M | 1.61M | -19.33M | -50.21M |
| Financing Cash Flow | 6.96M | 14.94M | 3.51M | 40.37M | 900.00K | 64.06M |
Avita Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCEL, the sentiment is Neutral. The current price of 15.22 is below the 20-day moving average (MA) of 15.93, above the 50-day MA of 13.48, and above the 200-day MA of 7.22, indicating a neutral trend. The MACD of 0.79 indicates Positive momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 23.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RCEL.
Avita Medical Risk Analysis
Avita Medical disclosed 39 risk factors in its most recent earnings report. Avita Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAvita Medical Peers Comparison
Overall Rating
BVS66Neutral
RCEL60Neutral
SNWV47Neutral
SRTS45Neutral
TELA43Neutral
IART40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | $881.37M | 12.35 | 27.23% | ― | 3.87% | 623.68% | |
| 60Neutral | $478.22M | -12.89 | 146.38% | ― | 16.96% | 34.83% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $15.57M | 5.90 | 113.13% | ― | -0.61% | ― | |
| 45Neutral | $38.52M | -2.41 | -38.65% | ― | -53.33% | -429.93% | |
| 43Neutral | $34.42M | -1.05 | 425.91% | ― | 1.46% | 15.79% | |
| 40Underperform | $1.09B | 84.36 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RCEL | Avita Medical Ltd | 15.22 | 11.27 | 285.32% | |
| IART | Integra Lifesciences | 13.98 | 2.83 | 25.38% | |
| SNWV | Sanuwave Health Inc. | 1.81 | -30.33 | -94.37% | |
| SRTS | Sensus Healthcare, Inc. | 2.34 | -1.70 | -42.08% | |
| TELA | Tela Bio, Inc. | 0.76 | -0.32 | -29.54% | |
| BVS | Bioventus, Inc. | 10.46 | 3.74 | 55.65% |
Avita Medical Corporate Events
Avita Medical Reports Warrant Exercise and Share Issuance
NeutralOn November 2, 2026, Avita Medical lodged filings with the ASX disclosing Perceptive Credit Holdings V, LP’s exercise of a warrant issued June 5, 2026, under a January 13, 2026 credit agreement. Perceptive exercised the warrant cashlessly on October...
Avita Medical Expands PermeaDerm Global Distribution Agreement
PositiveOn August 5, 2026, Avita Medical entered into a Global Amendment with Stedical Scientific that enhances its economic stake in PermeaDerm, raising its revenue share to 67% on sheet products and 80% on glove products, with potential adjustments if marg...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
